Live Breaking News & Updates on Phase 3 Clinical Trial

Stay updated with breaking news from Phase 3 clinical trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer. Patients will b ....

United States , Jane Chung , Anna Nayun Kim , Samsung Bioepis , Ilsun Hong , Drug Administration , Merck Sharp Dohme Corp , Samsung Bioepis Co Ltd , Ministry Of Food , Product Evaluation Team Leader Of Samsung Bioepis , Committee For Medicinal Products Human Use , European Medicines Agency , Vice President , Product Evaluation Team Leader , Merck Sharp , Drug Safety , Biologics License Application , Medicinal Products , Human Use , Nayun Kim , Phase 3 Clinical Trial , Iopharmaceutical Company , Clinical Trial , Iv Infusion , Vitamin Supplementation ,

Melanoma vaccine shows promise; approved for phase 3 trial

Orbis Health Solutions melanoma vaccine shows promising results in phase 2 trial, with high survival rates and minimal side effects. ....

Riley Polk , Orbis Health Solutions , Phase 3 Clinical Trial , Melanoma Vaccine , Cancer Vaccine , Umor Lysate Particle , Disease Free Survival , Cancer Treatment ,

BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious aut ....

Mont Saint Guibert , Waals Gewest , Science Park , Singapore General , France General , Trialcap Pte , Ghislaine Gasparetto , Neil Hunter Michelle Boxall , International Media Enquiries , Trialcap Fund , Rd Service , Clinical Research Organization , Global Investment Company , Ib Communications , Euronext Brussels , Term Sheet , Graft Versus Host Disease , Chief Executive Officer , Investment Company , Louvain La Neuve Science Park , Mesenchymal Stromal Cells , Chief Executive , Media Enquiries , French Investor Enquiries , Sprim Global Investments , Arsenic Trioxide ,

United States Clinical Trial Data Management Service Market

Dublin, Nov. 21, 2023 (GLOBE NEWSWIRE) The ....

United States , Cromos Pharma , Biotech Pharmaceutical Companies , Us Clinical Trial Data Management Service Market , Service Companies , Trial Data Management Service Market , Market Value , Fisher Scientific , Research And Markets , Contract Research Organization , Data Management , Ata Storage And Management , Phase 1 Clinical Trial , Phase 3 Clinical Trial ,

YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine

YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the completion of subject enrollment in its Phase 3 clinical trial (the "Phase 3 Trial" or the "Trial") of the Company's PIKA Rabies Vaccine. The Trial, which will assess the safety, immunogenicity, and lot-to-lot consis ....

United States , Alyssa Li , Muhammad Ahmad , Robin Yang , Zenaida Mojares , Ralph Villalobos , Source Ys Biopharma Co Ltd , Securities Exchange , Principal Investigator , Central Park Teaching Hospital , Philippine General Hospital , Chief Medical Officer , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Business Combination , Rabies Vaccine , Phase 3 Clinical Trial ,